ABSTRACT
Peripheral nerves and Schwann cells (SCs) are privileged and protected sites for initial colonization, survival, and spread of leprosy bacillus. Mycobacterium leprae strains that survive multidrug therapy show a metabolic inactivation that subsequently induces the recurrence of typical clinical manifestations of leprosy. Furthermore, the role of the cell wall phenolic glycolipid I (PGL-I) in the M. leprae internalization in SCs and the pathogenicity of M. leprae have been extensively known. This study assessed the infectivity in SCs of recurrent and non-recurrent M. leprae and their possible correlation with the genes involved in the PGL-I biosynthesis. The initial infectivity of non-recurrent strains in SCs was greater (27%) than a recurrent strain (6.5%). In addition, as the trials progressed, the infectivity of the recurrent and non-recurrent strains increased 2.5- and 2.0-fold, respectively; however, the maximum infectivity was displayed by non-recurrent strains at 12 days post-infection. On the other hand, qRT-PCR experiments showed that the transcription of key genes involved in PGL-I biosynthesis in non-recurrent strains was higher and faster (Day 3) than observed in the recurrent strain (Day 7). Thus, the results indicate that the capacity of PGL-I production is diminished in the recurrent strain, possibly affecting the infective capacity of these strains previously subjected to multidrug therapy. The present work opens the need to address more extensive and in-depth studies of the analysis of markers in the clinical isolates that indicate a possible future recurrence.
Subject(s)
Leprosy , Mycobacterium leprae , Humans , Mycobacterium leprae/genetics , Mycobacterium leprae/metabolism , Drug Therapy, Combination , Leprostatic Agents/metabolism , Leprosy/genetics , Glycolipids/metabolism , Antibodies/metabolism , Schwann Cells/metabolism , Antigens, Bacterial/metabolismABSTRACT
Several infections, such as pneumonia, urinary tract infections (UTIs), as well as bloodstream, skin, and soft tissue infections, are caused by Acinetobacter baumannii, a nosocomial pathogen and Gram-negative coccobacillus. Due to its resistance to a variety of medications, multidrug therapy, and occasionally pan therapies, this bacterium is a huge public health concern. Drug resistance is a big worry not only in A. baumannii, but it is also a major challenge in many other diseases. Antibiotic resistance, biofilm development, and genetic alterations are all linked to variables like the efflux pump. Efflux pumps are transport proteins involved in the extrusion of hazardous substrates from within cells into the external environment (including nearly all types of therapeutically relevant antibiotics). Both Gram-positive and Gram-negative bacteria, as well as eukaryotic organisms, contain these proteins. Efflux pumps may be specialized for a single substrate or can transport a variety of structurally dissimilar molecules (including antibiotics of many classes); these pumps have been linked to multiple drug resistance (MDR). There are five primary families of efflux transporters in the prokaryotic kingdom: MF (major facilitator), MATE (multidrug and toxic efflux), RND (resistance-nodulation-division), SMR (small multidrug resistance), and ABC (ATP-binding cassette). The efflux pumps and their types as well as the mechanisms of an efflux pump involved in multidrug resistance in bacteria have been discussed here. The main focus is on the variety of efflux pumps commonly found in A. baumannii, along with their mechanism by which they make this bacteria drug resistant. The efflux-pump-inhibitor-based strategies that are significant in targeting efflux pumps in A. baumannii have also been discussed. The connection of biofilm and bacteriophage with the efflux pump can prove as an efficient strategy for targeting efflux-pump-based resistance in A. baumannii.
Subject(s)
Acinetobacter baumannii , Acinetobacter baumannii/genetics , Anti-Bacterial Agents/pharmacology , Drug Therapy, Combination , Bacterial Proteins/metabolism , Gram-Negative Bacteria , Gram-Positive Bacteria/metabolism , Leprostatic Agents/metabolism , Drug Resistance, Multiple, Bacterial/geneticsABSTRACT
Human Raf1 kinase inhibitory protein (hRKIP) is an important modulator of the Ras/Raf1/MEK/ERK signaling pathway. Here, we demonstrated that anti-leprosy drug Clofazimine can bind to hRKIP with a significantly stronger affinity than the endogenous substrate phosphatidylethanolamine (PE) by using Biolayer interference technology. Moreover, we identified that residues P74, S75, K80, P111, P112, V177, and P178 play crucial roles in the binding of hRKIP to Clofazimine by using a combination of Nuclear Magnetic Resonance spectroscopy and molecular docking approach. These residues are located at the conserved ligand-binding pocket of hRKIP. Furthermore, we found that 3.2 µM Clofazimine could significantly increase the ERK phosphorylation level by about 37%. Our results indicate that Clofazimine can enhance Ras/Raf1/MEK/ERK signaling transduction pathway via binding to hRKIP. This work provides valuable hints for exploiting Clofazimine as a potential lead compound to efficiently treat the diseases related to RKIP or the Ras/Raf/MEK/ERK pathway.
Subject(s)
Clofazimine/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Phosphatidylethanolamine Binding Protein/metabolism , Binding, Competitive , Clofazimine/chemistry , Clofazimine/pharmacology , HEK293 Cells , Humans , Leprostatic Agents/chemistry , Leprostatic Agents/metabolism , Leprostatic Agents/pharmacology , MAP Kinase Signaling System/drug effects , Magnetic Resonance Spectroscopy , Molecular Docking Simulation , Molecular Structure , Phosphatidylethanolamine Binding Protein/chemistry , Phosphatidylethanolamines/chemistry , Phosphatidylethanolamines/metabolism , Phosphorylation/drug effects , Protein Binding , Protein DomainsABSTRACT
Leprosy is a chronic infection of skin and nerve caused by Mycobacterium leprae. The treatment is based on standard multi drug therapy consisting of dapsone, rifampicin and clofazamine. The use of rifampicin alone or with dapsone led to the emergence of rifampicin-resistant Mycobacterium leprae strains. The emergence of drug-resistant leprosy put a hurdle in the leprosy eradication programme. The present study aimed to predict the molecular model of ribonucleotide reductase (RNR), the enzyme responsible for biosynthesis of nucleotides, to screen new drugs for treatment of drug-resistant leprosy. The study was conducted by retrieving RNR of M. leprae from GenBank. A molecular 3D model of M. leprae was predicted using homology modelling and validated. A total of 325 characters were included in the analysis. The predicted 3D model of RNR showed that the Ï and φ angles of 251 (96.9%) residues were positioned in the most favoured regions. It was also conferred that 18 α-helices, 6 ß turns, 2 γ turns and 48 helix-helix interactions contributed to the predicted 3D structure. Virtual screening of Food and Drug Administration approved drug molecules recovered 1829 drugs of which three molecules, viz., lincomycin, novobiocin and telithromycin, were taken for the docking study. It was observed that the selected drug molecules had a strong affinity towards the modelled protein RNR. This was evident from the binding energy of the drug molecules towards the modelled protein RNR (-6.10, -6.25 and -7.10). Three FDA-approved drugs, viz., lincomycin, novobiocin and telithromycin, could be taken for further clinical studies to find their efficacy against drug resistant leprosy.
Subject(s)
Bacterial Proteins/chemistry , Drug Resistance, Bacterial , Leprostatic Agents/metabolism , Mycobacterium leprae/enzymology , Ribonucleotide Reductases/chemistry , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , Drug Delivery Systems , Leprostatic Agents/chemistry , Molecular Docking Simulation , Protein Binding , Ribonucleotide Reductases/antagonists & inhibitors , Ribonucleotide Reductases/metabolismABSTRACT
BACKGROUND: Dapsone (4,4'-diaminodiphenylsulfone) has been widely used for the treatment of infections such as leprosy. Dapsone hypersensitivity syndrome (DHS) is a major side effect, developing in 0.5-3.6% of patients treated with dapsone, and its mortality rate is â¼10%. Recently, human leukocyte antigen (HLA)-B*13:01 was identified as a marker of susceptibility to DHS. OBJECTIVES: To investigate why HLA-B*13:01 is responsible for DHS from a structural point of view. METHODS: First, we used homology modeling to derive the three-dimensional structures of HLA-B*13:01 (associated with DHS) and HLA-B*13:02 (not so associated despite strong sequence identity [99%] with HLA-B*13:01). Next, we used molecular docking, molecular dynamic simulations, and the molecular mechanics Poisson-Boltzman surface area method, to investigate the interactions of dapsone with HLA-B*13:01 and 13:02. RESULTS: We found a crucial structural difference between HLA-B*13:01 and 13:02 in the F-pocket of the antigen-binding site. As Trp95 in the α-domain of HLA-B*13:02 is replaced with the less bulky Ile95 in HLA-B*13:01, we found an additional well-defined sub-pocket within the antigen-binding site of HLA-B*13:01. All three representative docking poses of dapsone against the antigen-binding site of HLA-B*13:01 used this unique sub-pocket, indicating its suitability for binding dapsone. However, HLA-B*13:02 does not seem to possess a binding pocket suitable for binding dapsone. Finally, a binding free energy calculation combined with a molecular dynamics simulation and the molecular mechanics Poisson-Boltzman surface area method indicated that the binding affinity of dapsone for HLA-B*13:01 would be much greater than that for HLA-B*13:02. CONCLUSIONS: Our computational results suggest that dapsone would fit within the structure of the antigen-recognition site of HLA-B*13:01. This may change the self-peptides that bind to HLA-B*13:01, explaining why HLA-B*13:01 is a marker of DHS susceptibility.
Subject(s)
Dapsone/metabolism , Drug Hypersensitivity Syndrome/immunology , HLA-B Antigens/metabolism , Leprostatic Agents/metabolism , Leprosy/drug therapy , Computational Biology , Dapsone/adverse effects , Dapsone/immunology , Drug Hypersensitivity Syndrome/etiology , HLA-B Antigens/immunology , Humans , Leprostatic Agents/adverse effects , Molecular Docking Simulation , Molecular Dynamics Simulation , Protein Binding , Sequence Homology, Amino AcidABSTRACT
Thioamide drugs, ethionamide (ETH) and prothionamide (PTH), are clinically effective in the treatment of Mycobacterium tuberculosis, M. leprae, and M. avium complex infections. Although generally considered second-line drugs for tuberculosis, their use has increased considerably as the number of multidrug resistant and extensively drug resistant tuberculosis cases continues to rise. Despite the widespread use of thioamide drugs to treat tuberculosis and leprosy, their precise mechanisms of action remain unknown. Using a cell-based activation method, we now have definitive evidence that both thioamides form covalent adducts with nicotinamide adenine dinucleotide (NAD) and that these adducts are tight-binding inhibitors of M. tuberculosis and M. leprae InhA. The crystal structures of the inhibited M. leprae and M. tuberculosis InhA complexes provide the molecular details of target-drug interactions. The purified ETH-NAD and PTH-NAD adducts both showed nanomolar Kis against M. tuberculosis and M. leprae InhA. Knowledge of the precise structures and mechanisms of action of these drugs provides insights into designing new drugs that can overcome drug resistance.
Subject(s)
Ethionamide/pharmacology , Leprosy/drug therapy , Prothionamide/pharmacology , Tuberculosis/drug therapy , Antitubercular Agents/chemistry , Antitubercular Agents/metabolism , Antitubercular Agents/pharmacology , Bacterial Proteins/antagonists & inhibitors , Crystallography, X-Ray , Drug Design , Drug Resistance, Multiple, Bacterial , Ethionamide/chemistry , Ethionamide/metabolism , Humans , In Vitro Techniques , Leprostatic Agents/chemistry , Leprostatic Agents/metabolism , Leprostatic Agents/pharmacology , Models, Molecular , Mycobacterium avium Complex/drug effects , Mycobacterium avium Complex/enzymology , Mycobacterium avium-intracellulare Infection/drug therapy , Mycobacterium leprae/drug effects , Mycobacterium leprae/enzymology , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/enzymology , NAD/chemistry , NAD/metabolism , Oxidoreductases/antagonists & inhibitors , Prothionamide/chemistry , Prothionamide/metabolism , Tuberculosis, Multidrug-Resistant/drug therapyABSTRACT
Incubation of rat erythrocytes with the hydroxylated metabolites of aniline and dapsone (4-4'-diaminodiphenylsulfone), phenylhydroxylamine and dapsone hydroxylamine, respectively, induced marked release of iron and methemoglobin formation. On the contrary, no release of iron nor methemoglobin formation was seen when the erythrocytes were incubated with the parent compounds (aniline and dapsone). The acute intoxication of rats with aniline or dapsone induced a marked increase in the erythrocyte content of free iron and methemoglobin, indicating that the xenobiotics are effective only after biotransformation to toxic metabolites in vivo. Prolonged administration of aniline or dapsone to rats produced continuous release of iron from erythrocytes. Marked iron overload was seen in the spleen and in the liver Kupffer cells, as detected histochemically. The spleen weight in these subchronically treated animals was significantly increased. The free iron pool was markedly increased in the spleen and to a lower extent in the liver. The possible relationships between iron release in erythrocytes, oxidative damage seen in senescent cells, hemolysis, overwhelmed capacity of spleen and liver to keep iron in storage forms and subsequent increase in low molecular weight, catalitically active iron is discussed.
Subject(s)
Aniline Compounds/toxicity , Dapsone/toxicity , Erythrocytes/drug effects , Hemolysis , Iron/blood , Leprostatic Agents/toxicity , Liver/drug effects , Oxidants/toxicity , Spleen/drug effects , Aniline Compounds/metabolism , Animals , Dapsone/analogs & derivatives , Dapsone/metabolism , Dapsone/pharmacology , Erythrocytes/metabolism , Hydroxylamines/pharmacology , Leprostatic Agents/metabolism , Liver/metabolism , Male , Methemoglobin/metabolism , Organ Size/drug effects , Oxidants/metabolism , Rats , Rats, Sprague-Dawley , Spleen/metabolismABSTRACT
A simple HPLC method is described for the determination of clofazimine in mouse tissues and in serum. The main application of the method was the determination of the drug in mouse tissues after i.v. administration of nanocrystalline suspensions or liposomal encapsulated clofazimine. Tissues were extracted with a 10-fold (w/v) volume of an extraction solution consisting of methanol/glacial acetic acid 9:1 (v/v). Serum proteins were precipitated with a 2-fold volume of acetonitrile. Isocratic chromatography was performed using an anion exchange column (Nucleosil 100-5 SA, Macherey & Nagel) for separation. The mobile phase was a mixture of acetonitrile and 0.1 mol/l aqueous phosphoric acid (75:25, v/v), adjusted to pH 2.9 with sodium hydroxide solution. Absorption of the eluate was monitored at 495 nm. The assay was precise, simple to perform and fast. Recovery from tissues was > or = 98%, from nanoparticles > or = 98%, and from liposomes > or = 96%. No interference was observed in extracts from mouse liver, spleen, lungs and human serum.
Subject(s)
Clofazimine/metabolism , Leprostatic Agents/metabolism , Animals , Chromatography, High Pressure Liquid , Clofazimine/administration & dosage , Clofazimine/blood , Drug Carriers , Humans , Leprostatic Agents/administration & dosage , Leprostatic Agents/blood , Liposomes , Mice , Reproducibility of ResultsABSTRACT
Thalidomide is effective in the treatment of inflammatory conditions like erythema nodosum leprosum in leprosy patients, and aphthous ulcers in AIDS patients. Its mechanism of action is uncertain and reports of its effect on the synthesis of inflammatory cytokines such as IL-2 and TNF-alpha are contradictory. As thalidomide is labile to spontaneous hydrolysis at pH 7.4, studies were carried out to explore the effects of deliberate hydrolysis or the ability of thalidomide to modulated cytokine production by human mononuclear cells stimulated in vitro with Staphylococcal enterotoxin A (SEA)(IL-2) or lipopolysaccharide from Salmonella minnesota (LPS)(TNF-alpha). Unhydrolyzed thalidomide at 4.0 micrograms/ml consistently enhanced the synthesis of IL-2 in SEA-stimulated cells, and suppressed the synthesis of TNF-alpha in LPS-stimulated cells; whereas, hydrolyzed thalidomide had no enhancing effect on SEA stimulated-cell synthesis of IL-2 or suppressive effect on LPS stimulated-cell synthesis of TNF-alpha. These findings demonstrate that thalidomide's ability in vitro to enhance IL-2 and to suppress TNF-alpha in stimulated cells is dependent on the intact molecule and underscore the necessity to employ thalidomide under appropriate physicochemical conditions.
Subject(s)
Interleukin-2/biosynthesis , Leprostatic Agents/metabolism , Leprostatic Agents/pharmacokinetics , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Thalidomide/metabolism , Thalidomide/pharmacokinetics , Tumor Necrosis Factor-alpha/biosynthesis , Biotransformation , Female , Humans , Hydrolysis , Interleukin-2/blood , Male , Stimulation, ChemicalABSTRACT
Dapsone toxicity is putatively initiated by formation of a hydroxylamine metabolite by cytochromes P450. In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM). Troleandomycin (40 mumol/L) inhibited hydroxylamine formation at 100 mumol/L dapsone by 50%; diethyldithiocarbamate (150 mumol/L) and tolbutamide (400 mumol/L) inhibited at 5 mumol/L dapsone by 50% and 20%, respectively, suggesting that the low-affinity isozyme is CYP3A4 and the high-affinity isozymes are 2E1 and 2C. Disulfiram, 500 mg, 18 hours before a 100 mg oral dose of dapsone in healthy volunteers, diminished area under the hydroxylamine plasma concentration-time curve by 65%, apparent formation clearance of the hydroxylamine by 71%, and clearance of dapsone by 26%. Disulfiram produced a 78% lower concentration of methemoglobin 8 hours after dapsone.
Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Dapsone/analogs & derivatives , Dapsone/metabolism , Leprostatic Agents/metabolism , Microsomes, Liver/metabolism , Oxidoreductases, N-Demethylating/metabolism , Adult , Alcohol Deterrents/pharmacology , Anti-Bacterial Agents/pharmacology , Cytochrome P-450 CYP2E1 , Dapsone/pharmacokinetics , Disulfiram/pharmacology , Drug Interactions , Female , Humans , Hydroxylation/drug effects , Leprostatic Agents/pharmacokinetics , Male , Microsomes, Liver/drug effects , Troleandomycin/pharmacologyABSTRACT
Rifampicin (I) was converted into two inactivated products RIP-Ma and RIP-Mb by Mycobacterium smegmatis DSM43756. MS, NMR and chromatographic analysis showed the compounds to be 3-formyl-23-[O-(alpha-D-ribofuranosyl)]rifamycin SV (6) and 23-[O-(alpha-D-ribofuranosyl)]rifampicin (7), respectively.
Subject(s)
Antibiotics, Antitubercular , Leprostatic Agents , Mycobacterium/metabolism , Ribose/metabolism , Rifampin/chemistry , Rifampin/metabolism , Antibiotics, Antitubercular/chemistry , Antibiotics, Antitubercular/metabolism , Biotransformation , Drug Resistance, Microbial , Leprostatic Agents/chemistry , Leprostatic Agents/metabolism , Magnetic Resonance Spectroscopy , Molecular Structure , Ribose/chemistry , Rifampin/analogs & derivativesABSTRACT
The paper deals with the experimental and clinical study of a new implantable therapeutical means based on biocompatible implants containing the antituberculous agent benemycin. The developed implantant having 4 coatings releases within 10 days as high as 37% of the applied drug benemycin. Then within further 30-70 days, release of the drug is 0.7% a day. The parallel bacteriological studies with the operative material placed in agar made 30-60 days after surgery have indicated that growth retardment in rabbits is 17-30 mm, which corresponds to the levels of rifandin (0.125-1.0 microgram/g tissue. The developed implantant has been used in 130 cases of the surgical treatment of tuberculous spondylitis in order to replace a defect of the body of a vertebra and to make a depot for the antituberculous drug just in the focus. Formation of the pulley at the site of intervention was noted in 57 (43.8%) cases within 5 months and in 62 (47.7%) cases within 10 months. The developed implantant has no toxicity and produces no allergic reactions. The position results of the treatment allows it to be recommended for use in clinical practice.
Subject(s)
Biocompatible Materials , Prostheses and Implants , Rifampin/therapeutic use , Spondylitis/therapy , Thoracic Vertebrae , Tuberculosis, Osteoarticular/therapy , Adult , Aged , Animals , Combined Modality Therapy , Drug Implants , Female , Follow-Up Studies , Humans , Leprostatic Agents/metabolism , Male , Middle Aged , Rabbits , Rifamycins/metabolism , Spondylitis/metabolism , Treatment Outcome , Tuberculosis, Osteoarticular/metabolismABSTRACT
The simultaneous analysis of main antileprosy drugs such as 4,4'-diaminodiphenyl sulfone (DDS), clofazimine, rifampicin and their main metabolites in serum was examined by high-performance liquid chromatography using a muBondapak C18 column. When the drugs dissoluted from serum were developed by tetrahydrofuran-0.5% acetic acid (40:60), clofazimine and rifampicins could be analyzed separately. Apart from the mutual separation of water-soluble conjugates of DDS, the individual analysis of DDS, its main liposoluble metabolite and a few related sulfone compounds is possible when the drugs are first developed by acetonitrile-water (20:80). By the use of tetrahydrofuran-water (50:50) containing PIC B-5, the rapid measurement of clofazimine isolated from the other compounds is also possible.
Subject(s)
Leprostatic Agents/blood , Animals , Chemical Phenomena , Chemistry , Chromatography, High Pressure Liquid/methods , Clofazimine/blood , Clofazimine/metabolism , Dapsone/blood , Dapsone/metabolism , Guinea Pigs , Humans , Leprostatic Agents/metabolism , Reference Values , Rifampin/blood , Rifampin/metabolismABSTRACT
The Memorandum reviews the considerable progress that has been made in research on the chemotherapy of leprosy during the last 10-15 years, as a result of which it is now possible to study the same topics in leprosy as are studied in other bacterial diseases. Thus drugs have been screened in mice for their activity against Mycobacterium leprae. Those that have been found to have the greatest activity against M. leprae at acceptable dosages-dapsone, rifampicin, and clofazimine-have been characterized in terms of the minimal effective dosage and rate of bacterial kill. Similarly, their pharmacokinetics in man and in certain animals have been defined. The theoretical basis for drug trials in leprosy patients is discussed in terms of the number of viable and the number of dead M. leprae that remain at various stages of therapy.
Subject(s)
Leprosy/drug therapy , Animals , Drug Evaluation , Drug Evaluation, Preclinical , Humans , Leprostatic Agents/administration & dosage , Leprostatic Agents/metabolism , Leprostatic Agents/therapeutic use , MiceABSTRACT
The Memorandum reviews the considerable progress that has been made in research on the chemotherapy of leprosy during the last 10-15 years, as a result of which it is now possible to study the same topics in leprosy as are studied in other bacterial diseases. Thus drugs have been screened in mice for their activity against Mycobacteerium leprae. Those that have been found to have the greatest activity against M. leprae at acceptable dosages-dapsone, rifampicin, and clofazimine-have been characterized in terms of the minimal effective dosage and rate of bacterial kill. Similarly, their pharmacokinetics in man and in certain animals have been defined. The theoretical basis for drug trials in leprosy patients is discussed in terms of the number of viable and the number of dead M.leprae that remain of various stages of therapy